Bloating affects roughly 30% of adults, and gastrointestinal changes are common when starting GLP-1 medications like semaglutide
Ultimately, the aim is to determine how much current the battery can deliver while maintaining safe operating temperatures
Elevated resting heart rate in a dose-dependent pattern, most pronounced at higher doses Reduced systolic and diastolic blood pressure across all dose groups No significant increase in major adverse cardiovascular events including heart attack or stroke No reported cases of serious arrhythmia directly attributed to the drug in the trial population Mild palpitations reported by some participants, consistent with the heart rate increase The palpitation reports are worth noting
In contrast, when analyzing stroke outcomes, the effect was more pronounced with GLP-1 RAs, which provided the greatest contribution to the reduction of stroke events
Guernsey doctor Mayoni Gooneratne said the incoming price increases of 122 to 330 for a month's supply would cause a wealth divide in healthcare
The following is an analysis from the aspects of mechanism, clinical evidence, influencing factors and optimization directions